Silverback Therapeutics Forecast, price target & analysts
Silverback Therapeutics Target price 2025 - Analyst rating & recommendation
Silverback Therapeutics Classifications & Recommendation:
Silverback Therapeutics Price Target
| Target Price | $32.50 |
| Price | $10.20 |
| Potential |
218.63%
register free of charge
|
| Number of Estimates | 4 |
|
4 Analysts have issued a price target Silverback Therapeutics 2026 .
The average Silverback Therapeutics target price is $32.50.
This is
218.63%
register free of charge
$40.00
292.16%
register free of charge
$27.00
164.71%
register free of charge
|
|
| A rating was issued by 5 analysts: 5 Analysts recommend Silverback Therapeutics to buy, 0 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Silverback Therapeutics stock has an average upside potential 2026 of
218.63%
register free of charge
|
Sales and Margin forecast 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million $ | 0.03 | 18.04 |
| 97.73% | 60,031.33% | |
| EBITDA Margin | -224,833.33% | -142.99% |
| 8,331.25% | 99.94% | |
| Net Margin | -184,585.00% | -258.50% |
| 2,782.76% | 99.86% |
5 Analysts have issued a sales forecast Silverback Therapeutics 2024 . The average Silverback Therapeutics sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued an EBITDA forecast Silverback Therapeutics 2024 . The average Silverback Therapeutics EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
3 Silverback Therapeutics Analysts have issued a net profit forecast 2024. The average Silverback Therapeutics net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.57 | -0.48 |
| 34.48% | 15.79% | |
| P/E | negative | |
| EV/Sales | 43.61 |
3 Analysts have issued a Silverback Therapeutics forecast for earnings per share. The average Silverback Therapeutics <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Silverback Therapeutics stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Silverback Therapeutics...
Current Silverback Therapeutics Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Raymond James | Locked ➜ Locked | Locked | Jan 14 2025 |
| Leerink Partners | Locked ➜ Locked | Locked | Jan 13 2025 |
| Cantor Fitzgerald | Locked ➜ Locked | Locked | Oct 08 2024 |
| Leerink Partners | Locked ➜ Locked | Locked | Sep 20 2024 |
| Cantor Fitzgerald | Locked ➜ Locked | Locked | Sep 16 2024 |
| Cantor Fitzgerald | Locked ➜ Locked | Locked | Sep 09 2024 |
| Cantor Fitzgerald | Locked ➜ Locked | Locked | Aug 20 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Raymond James: Locked ➜ Locked
|
Jan 14 2025 |
|
Locked
Leerink Partners: Locked ➜ Locked
|
Jan 13 2025 |
|
Locked
Cantor Fitzgerald: Locked ➜ Locked
|
Oct 08 2024 |
|
Locked
Leerink Partners: Locked ➜ Locked
|
Sep 20 2024 |
|
Locked
Cantor Fitzgerald: Locked ➜ Locked
|
Sep 16 2024 |
|
Locked
Cantor Fitzgerald: Locked ➜ Locked
|
Sep 09 2024 |
|
Locked
Cantor Fitzgerald: Locked ➜ Locked
|
Aug 20 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
